Miss a weekly Ozempic injection, and your body starts reclaiming lost weight almost immediately — a rebound problem that haunts every GLP-1 drug on the market. That metabolic boomerang is exactly what scientists at The Wistar Institute are targeting. Their approach: a single DNA injection that kept diabetic mice lean and glucose-stable for 70 days, roughly 10 times longer than semaglutide managed in head-to-head testing. This is mouse data — important caveat, more on that shortly — but the underlying platform has already worked in humans for a different purpose, which makes it worth paying attention to. If you’re managing metabolic health in the meantime, avoiding common keto diet pitfalls can make a meaningful difference.
How the DNA Injection Actually Works
The mechanism turns your muscle cells into a continuous, on-site drug factory.
Wistar researchers engineered small circular DNA instructions — plasmid DNA — that tell muscle cells to produce long-acting versions of GLP-1 and GIP, the gut hormones that Ozempic and Mounjaro mimic. A brief electrical pulse drives the DNA inside those cells. From there, they churn out therapeutic protein continuously, protected by an antibody fragment that prevents rapid breakdown in the body.
“Instead of delivering a drug that will get cleared by the body, we’re giving cells the instructions to make that drug themselves, and they keep making it,” said lead scientist Ebony Gary, Ph.D., of the Wistar Institute’s Vaccine and Immunotherapy Center.
The team also used AI-assisted structural modeling to create pSynCretin — a synthetic molecule engineered to activate both GLP-1 and GIP receptors simultaneously, conceptually similar to tirzepatide (Mounjaro). Duration matters here because GLP-1 drugs degrade fast, which is precisely why weekly injections exist in the first place. Adding credibility to the approach: this same DNA electroporation platform already sustained COVID-19 antibody production in human subjects for over 72 weeks in a Phase 1 trial, according to Wistar. That’s genuine clinical precedent, not just a promising slide deck. In a similar vein of AI-driven biomedical innovation, one man used AI to develop a cancer vaccine that saved his dog’s life.
What This Isn’t (Yet)
Preclinical results are encouraging, but significant unknowns remain before any human application.
Published in Trends in Biotechnology (2026), this work remains firmly preclinical. Plasmid DNA is eventually cleared by the body, so “one shot forever” is not the claim — realistic human dosing intervals would likely run weeks to months rather than lifetime coverage. Safety questions around the following are still wide open territory for future clinical trials:
- immune reactions
- off-target protein expression
- consequences of sustained appetite suppression
The broader ambition, though, is genuinely compelling. Think of the platform as a streaming service for therapeutics — one delivery system, continuous output, and content that can be swapped depending on clinical need. Wistar researchers are already investigating whether long-acting incretins influence cancer outcomes and inflammatory conditions like arthritis and psoriasis, where conventional GLP-1 drugs have shown early promise.
“Once we have this toolkit, we can think about making novel proteins that didn’t exist before and engineering them from the ground up to do exactly what we need them to do,” Gary noted.
Rebound weight gain after stopping GLP-1 therapy is a well-documented clinical frustration. This research does not solve that tomorrow. What it does is sketch a credible path toward metabolic disease management that looks more like a procedure than a perpetual prescription — and that distinction alone is worth watching as human trials move closer to the horizon.
